Clinical Trials Logo

Advanced Solid Neoplasms clinical trials

View clinical trials related to Advanced Solid Neoplasms.

Filter by:
  • None
  • Page 1

NCT ID: NCT03742895 Recruiting - Clinical trials for Advanced Solid Neoplasms

Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)

Start date: December 12, 2018
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy and safety of olaparib (MK-7339) monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic) that: 1) have progressed or been intolerant to standard of care therapy; and 2) are positive for homologous recombination repair mutation (HRRm) or homologous recombination deficiency (HRD).

NCT ID: NCT03359733 Withdrawn - Lymphoma, Malignant Clinical Trials

A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid Tumor

Start date: February 28, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to characterize the effect of food on the single-dose PK of TAK-659 in participants with advanced solid tumors and/or lymphomas.

NCT ID: NCT03338881 Withdrawn - Clinical trials for Advanced Solid Neoplasms

A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma Malignancies

Start date: May 10, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the mass balance and to characterize the pharmacokinetics (PK) in plasma and urine, and of total radioactivity in plasma and whole blood following a single oral dose of [14C]-TAK-659 solution containing 60 to 80 micro curie (Ci) of total radioactivity in participants with advanced solid tumors and/or lymphomas.

NCT ID: NCT02829099 Completed - Clinical trials for Advanced Solid Neoplasms

A Study of Safety, Pharmacokinetics and Pharmacodynamics of JNJ-64457107 in Participants With Advanced Stage Tumors

Start date: September 21, 2016
Phase: Phase 1
Study type: Interventional

The primary purpose of the study is to determine the recommended Phase 2 dose (RP2D) and schedule of JNJ-64457107 when administered intravenously (IV) to participants with advanced stage solid tumors in Part 1 and to further characterize the safety of JNJ-64457107 when administered IV to participants with non-small cell lung cancer (NSCLC), pancreatic cancer and cutaneous melanoma in Part 2.